Cancer immunotherapy without frontiers: 2nd Annual Immuno-Oncology Meeting of the Centro de Investigación de Cancer en Sonora (CICS), Ciudad Obregón, Sonora México, Dec 2–4, 2016
This meeting in immuno-oncology brought together clinicians and scientists from United States, Canada, and México with the goal of breaking down international walls and establishing new collaborations.
Adoptive T-cell therapy
Bi-specific T-cell engager
Chimeric antigen receptor
Centro de Investigación de Cancer en Sonora
High-grade serous ovarian cancer
Inflammatory breast cancer
Melanoma Differentiation-Associated protein 5
Myeloid-derived suppressor cell
Pancreatic intraepithelial neoplasia
Pancreatic ductal adenocarcinoma
Polyinosinic polycytidylic acid
Single-chain variable fragment
The cancer genome atlas
Toll-like receptor 3
T regulatory cell
This work was supported by grant from the National Cancer Institute of the National Institutes of Health, R01CA157303, and by start-up funds from Augusta University Cancer Center and the Georgia Research Alliance (GRA). Esteban Celis holds the Cecil F. Whitaker Jr. MD/GRA Eminent Scholar Chair in Tumor Immunology.
Compliance with ethical standards
Conflict of interest
Esteban Celis has filed patent applications based on the use of synthetic peptides and poly-IC combinatorial vaccines. The rights of the patent applications have been transferred to the Moffitt Cancer Center (Tampa, FL). All the other authors do not have any conflict of interest.